CNV

Mission Bio Partners with S2 Genomics to Offer Robust Solid Tumor Sample Prep for Single-Cell DNA Analysis

Retrieved on: 
Dienstag, April 19, 2022
CEO, Health, Mayfield (company), DNA, Workflow, Pancreatic cancer, Association, Memorial Sloan Kettering Cancer Center, Research, MD, Center, Doctor of Philosophy, Glioblastoma, SAN, Neoplasm, Genomics, MSKCC, CNV, Agilent Technologies, Breast cancer, Biochemistry, Agriculture, Solution, American Association for Cancer Research, Chemistry (relationship), American Association, Partnership, AACR, B cell, Therapy, Cancer, Pharmaceutical industry, Medical imaging, New World Tapestry

SOUTH SAN FRANCISCO, Calif., April 19, 2022 /PRNewswire/ -- Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced a co-marketing partnership with S2 Genomics, Inc., a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications, to offer a single streamlined workflow for solid tumor applications from sample prep through analysis. The automated nuclei extraction-and-analysis workflow has been validated by the laboratory of Christine A. Iacobuzio-Donahue, MD, PhD, Director of the Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center (MSKCC), who shared her findings last week at the American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • Single-cell DNA analysis has transformed cancer research, supporting high-resolution insights into tumor heterogeneity that have led to a series of high-profile publications on disease mechanisms.
  • But challenges are greater for solid tumor profiling, where existing prep workflows often fail to produce sufficient cells or nuclei to provide meaningful results.
  • "We are eager to partner with leading companies to address key challenges to sample prep in solid tumor research," said Yan Zhang, PhD, CEO of Mission Bio.
  • S2 Genomics, founded in 2016, is a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications.

Mission Bio Partners with S2 Genomics to Offer Robust Solid Tumor Sample Prep for Single-Cell DNA Analysis

Retrieved on: 
Dienstag, April 19, 2022
CEO, Health, Mayfield (company), DNA, Workflow, Pancreatic cancer, Association, Memorial Sloan Kettering Cancer Center, Research, MD, Center, Doctor of Philosophy, Glioblastoma, SAN, Neoplasm, Genomics, MSKCC, CNV, Agilent Technologies, Breast cancer, Biochemistry, Agriculture, Solution, American Association for Cancer Research, Chemistry (relationship), American Association, Partnership, AACR, B cell, Therapy, Cancer, Pharmaceutical industry, Medical imaging, New World Tapestry

SOUTH SAN FRANCISCO, Calif., April 19, 2022 /PRNewswire/ -- Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced a co-marketing partnership with S2 Genomics, Inc., a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications, to offer a single streamlined workflow for solid tumor applications from sample prep through analysis. The automated nuclei extraction-and-analysis workflow has been validated by the laboratory of Christine A. Iacobuzio-Donahue, MD, PhD, Director of the Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center (MSKCC), who shared her findings last week at the American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • Single-cell DNA analysis has transformed cancer research, supporting high-resolution insights into tumor heterogeneity that have led to a series of high-profile publications on disease mechanisms.
  • But challenges are greater for solid tumor profiling, where existing prep workflows often fail to produce sufficient cells or nuclei to provide meaningful results.
  • "We are eager to partner with leading companies to address key challenges to sample prep in solid tumor research," said Yan Zhang, PhD, CEO of Mission Bio.
  • S2 Genomics, founded in 2016, is a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications.

Bionano Genomics Announces Publication of a New Study Using OGM Combined with Multiple Analytical Methods Including Single-Cell Analysis as a Comprehensive Molecular Strategy to Characterize the Genomic Variation in B-cell Acute Lymphoblastic Leukemia

Retrieved on: 
Mittwoch, April 6, 2022
MLPA, Adoption, B-ALL, Company, Private Securities Litigation Reform Act, Method, Autism, Karyotype, Genomics, Hospital Insurance and Diagnostic Services Act, Forward-looking statement, Lineagen, Aneuploidy, Adult, Cytogenetics, Research, Doctor of Philosophy, UZ Leuven, Medicine, U.S. Securities and Exchange Commission, University Hospitals Cleveland Medical Center, ALL, Genome, Software, Biology, Acute lymphoblastic leukemia, COVID-19, Genetic variation, OGM, GLOBE, SVS, Solution, CNV, SNV calling from NGS data, SAN, Annual report, RT-PCR, Patient, Security (finance), Vaccine, Risk management

In this study, from the University Hospitals Leuven, Belgium, researchers used a combination of methods to characterize genetic variation in samples from 12 subjects with B-ALL (11 pediatric, 1 adult).

Key Points: 
  • In this study, from the University Hospitals Leuven, Belgium, researchers used a combination of methods to characterize genetic variation in samples from 12 subjects with B-ALL (11 pediatric, 1 adult).
  • Conventional understanding suggests that cancer development, including B-ALL, can result from an accumulation of genetic changes that lead to unchecked cell growth.
  • As observed in this study, genetic variants associated with cancer development include SNVs, CNVs, and SVs.
  • Different methods are required to characterize the full spectrum of genetic variations present in a sample.

NuProbe QASeq Technology Enables Simultaneous Ultrasensitive Detection of CNVs and Mutations from FFPE Tissue and cfDNA

Retrieved on: 
Dienstag, April 5, 2022
Dai, Method, Cancer, Nucleic acid thermodynamics, Biomarker, DRS, DNA, Â, Loss, PCR, FISH, Research, NGS, Genomics, General manager, Precision medicine, RNA, Monroe Dunaway Anderson, Nature Communications, Mutation, GLOBE, Gene, VAF, DdPCR, Breast cancer, CNV, Patient, Prognosis, Vaccine, Medical imaging, Medical device

The results show detection of CNVs down to 5% heterozygous single copy gain or loss, and mutations down to 0.1% variant allele frequency (VAF), from both formalin-fixed, paraffin-embedded (FFPE) tissue samples and from cell-free DNA (cfDNA) samples[1].

Key Points: 
  • The results show detection of CNVs down to 5% heterozygous single copy gain or loss, and mutations down to 0.1% variant allele frequency (VAF), from both formalin-fixed, paraffin-embedded (FFPE) tissue samples and from cell-free DNA (cfDNA) samples[1].
  • However, these methods are limited in their multiplexing, and typically no more than about four genes can be profiled for CNVs with these methods.
  • Ueno, Reuben, and Barcenas at MD Anderson applying QASeq to breast cancer samples have demonstrated the unique capabilities of QASeq.
  • The simultaneous CNV and mutation profiling capabilities of QASeq allow NuProbe to provide our biopharma partners with powerful patient stratification tools.

Bionano Genomics Announces its Participation at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting with Six Posters and All of its On-Market Solutions on Display

Retrieved on: 
Mittwoch, März 23, 2022
Adoption, Company, Private Securities Litigation Reform Act, Lists of diseases, Autism, Leadership, LDT, American College of Medical Genetics and Genomics, Lineagen, Hospital Insurance and Diagnostic Services Act, Forward-looking statement, Medical genetics, CNV, Genetics, Research, Doctor of Philosophy, Medicine, CEO, U.S. Securities and Exchange Commission, Multi, Genome, Software, Trial of the century, Biology, Lists of publishing companies, American College, COVID-19, OGM, GLOBE, Solution, SAN, Annual report, Patient, ACMG, Security (finance), Video game, Medical imaging, Genomics

In addition to having six posters that present advances in clinical genetics research, Bionano will exhibit its complete portfolio of products and services as one company with more solutions.

Key Points: 
  • In addition to having six posters that present advances in clinical genetics research, Bionano will exhibit its complete portfolio of products and services as one company with more solutions.
  • The main ACMG conference sessions take place fromMarch 2326, 2022, in Nashville, TN with a virtual attendance option.
  • Bionano acquired Lineagen in August 2020 and sells Lineagens menu of laboratory developed tests (LDTs) for pediatric neurodevelopmental disorders, including autism spectrum disorder.
  • Bionano has evolved significantly in the last two years and we are now one team with more solutions that can benefit genetic clinicians and researchers.

Concave Finance launches to the public on 31st March 2022

Retrieved on: 
Donnerstag, März 31, 2022
Stakers, Decentralized finance, Gloria Bonder, Farm, Research, SPOON, Health, NFT, Staker Wallace, Climate, Delta neutral, Solution, Treasury, Securities research, CNV, Partnership, Cryptocurrency, Concave

NEW YORK, March 30, 2022 /PRNewswire/ -- In the Decentralized Finance space, Concave is a community-driven, Decentralized Finance (DeFi) protocol that aims to bring value to investors through the development of innovative DeFi products and active treasury management. At launch, Concave will introduce several novel solutions to grow its treasury whilst ensuring long-term investors receive the highest returns.

Key Points: 
  • At launch, Concave will introduce several novel solutions to grow its treasury whilst ensuring long-term investors receive the highest returns.
  • Each miner's (term used for their community) effort represents the heartbeat of Concave; without it Concave would not exist.
  • This balance is achieved by focusing on delivering value to long-term stakers via Bonding and Liquid Staking Mechanisms with anti-dilutive rewards.
  • Designed to capture sustainable long-term and navigate through all market conditions, Concave is here to stay.

Mission Bio Launches First-in-Class Single-Cell Genomics Solid Tumor Solution on Tapestri Platform

Retrieved on: 
Dienstag, März 29, 2022
Private Securities Litigation Reform Act, Cell, Biomarker, Glioblastoma, Therapy, DNA, Growth, HIV disease progression rates, Colorectal cancer, B cell, Agilent Technologies, Doctor of Philosophy, SEC, Risk, Research, Memorial Sloan Kettering Cancer Center, Neoplasm, Cancer, CEO, Health, Failure, U.S. Securities and Exchange Commission, Mayfield (company), MSKCC, Security (finance), Genome, Center, Safety, Solution, Architecture, COVID-19, Time, Workflow, Melanoma, SNV calling from NGS data, SAN, Breast cancer, CNV, Disease, Large-cell lung carcinoma, Medical imaging, Vaccine, Pharmaceutical industry, Mobile phone, New World Tapestry

SOUTH SAN FRANCISCO, Calif., March 29, 2022 /PRNewswire/ -- Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today launched the Tapestri Solution for Solid Tumor Research. This new end-to-end single-cell DNA sequencing workflow on the Tapestri Platform includes nuclei isolation prep protocol, pre-designed research panels for breast cancer and glioblastoma multiforme, and an improved single-cell copy number variation (CNV) bioinformatic analysis tool. Through the new capabilities, Mission Bio now offers solid tumor coverage in addition to hematologic cancers, where researchers routinely utilize Tapestri to probe tumor heterogeneity and leverage it for new understandings of clonal diversity and architecture underlying disease progression, biomarkers, and clinical practice.

Key Points: 
  • Tapestri Solution for Solid Tumor Researchoffers improved CNV analysis capability, in
    SOUTH SAN FRANCISCO, Calif., March 29, 2022 /PRNewswire/ -- Mission Bio, Inc. , the pioneer in high-throughput single-cell DNA and multi-omics analysis, today launched the Tapestri Solution for Solid Tumor Research .
  • The commercial launch of Mission Bio's Tapestri Solution for Solid Tumor Research highlights the company's continued dedication to enabling cancer research at a higher resolution more broadly with single-cell DNA sequencing.
  • To drive best practices for solid tumor single-cell DNA profiling, Mission Bio recently announced its first Center of Excellence at Memorial Sloan Kettering Cancer Center (MSKCC).
  • For more on Mission Bio and the Tapestri platform, please visit missionbio.com .

Vela Diagnostics Launches Focused (60 Genes) and Comprehensive (525 Genes) NGS-Based Pan-Cancer Panels

Retrieved on: 
Montag, März 28, 2022
Biomarker, TMB, Microsatellite instability, DNA, Indel, Clinical trial, IVD, PCR, Oncovirus, Bacteria, Panel, NGS, Cancer, Precision medicine, RNA, CEO, VELA, Sentosa, Neoplasm, Laboratory, Name, QC, SL, Infection, 60, Workflow, Gene, UMI, Solution, SNV calling from NGS data, CNV, MSI, Fine chemical, Medical imaging, Illumina

HAMBURG, Germany, March 28, 2022 /PRNewswire/ -- Vela Diagnostics announced today the launch of its new OncoKey SL 60 and 525 Plus Panels.

Key Points: 
  • HAMBURG, Germany, March 28, 2022 /PRNewswire/ -- Vela Diagnostics announced today the launch of its new OncoKey SL 60 and 525 Plus Panels.
  • Vela Diagnostics offers two pan-cancer gene panels: the focused OncoKey SL 60 Plus Panel, and the comprehensive OncoKey SL 525 Plus Panel.
  • "Vela Diagnostics is planning to launch our OncoKey 60 and 525 Plus Panels in Q4 2022 in the USA and Asia Pacific," said Sam Dajani, CEO and Executive Chairman of Vela Diagnostics.
  • "Using these panels on Vela Diagnostics' automated workflow will reduce human error and minimize sample cross contamination which can be generated by using a manual workflow.

Osaka Gas Singapore to Undertake Joint Methanation Study in Singapore

Retrieved on: 
Freitag, März 18, 2022
Chemicals, Plastics, Oil, Gas, Manufacturing, Alternative Energy, Energy, Research, Science, Carbon, Osaka Gas, Hydrogen, Multimedia, CO2, Research, Methane, Carbon dioxide, Methanation, Electricity, Gas, INPEX, Electrolysis, Luther Burbank: His Methods and Discoveries, Their Practical Application, OGS, SOEC, Efficiency, Technology, CNV, City, Natural gas, Coal

Osaka Gas Co., Ltd. (Osaka Gas) today announced its wholly owned subsidiary, Osaka Gas Singapore Pte.

Key Points: 
  • Osaka Gas Co., Ltd. (Osaka Gas) today announced its wholly owned subsidiary, Osaka Gas Singapore Pte.
  • Ltd. (as Trustee of City Energy Trust) and City-OG Gas Energy Services Pte.
  • Ltd. (City-OG) to conduct a feasibility study on a methanation project in Singapore.
  • Aiming to become carbon neutral by 2050 under CNV, Osaka Gas has also been developing other methanation projects such as the methanation technical development with INPEX in Nagaoka city, Niigata prefecture1, the innovative methanation (SOEC methanation) basic research to synthesize methane with a high energy conversion efficiency using renewable energy2 and the joint study with ATCO Australia Pty Ltd on methanation project in Australia3.

Health Canada Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab)

Retrieved on: 
Donnerstag, März 10, 2022
Risk, Pharmacokinetics, CADTH, Neuroscience, Central retinal vein occlusion, CNV, Diabetic retinopathy, Samsung, Nobel Prize, LinkedIn, Safety, AMD, United Kingdom, Infliximab, Regulatory affairs, GLOBE, Patient, NOC, Macular edema, Neovascularization, RVO, Biotechnology, Inclusion, Lists of diseases, Health Canada, Pathology, General manager, Endocrinology, Culture, Visual impairment, Trastuzumab, Treatment, Ophthalmology, Multiple sclerosis, Hematology, Twitter, Ranibizumab, Adalimumab, Spinal muscular atrophy, Severe cognitive impairment, Bevacizumab, Gastroenterology, Choroidal neovascularization, Social media, Biosimilar, Health care, Genentech, DME, Generic drug, Pharmaceutical industry, Health insurance, EU, Biogen, Woman

Health Canada granted a Notice of Compliance (NOC) for BYOOVIZ on March 8, making it the first and only ranibizumab biosimilar to receive regulatory approval in Canada to date.

Key Points: 
  • Health Canada granted a Notice of Compliance (NOC) for BYOOVIZ on March 8, making it the first and only ranibizumab biosimilar to receive regulatory approval in Canada to date.
  • The approval is part of our commitment to providing a treatment option for patients with retinal vascular disorders in Canada.
  • The Health Canada approval was based on a totality of evidence including quality, non-clinical data, and clinical data.
  • In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc. for two ophthalmology biosimilar candidates, SB11 (ranibizumab) and SB15 (aflibercept).